Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy
Shihong Zhou, Ying Zhang, Ziheng Wu, Pinghui Xia, Tianyu He, Jinlin Cao, Wang Lv, Jian Hu · 2024
Read Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy by Shihong Zhou, Ying Zhang, Ziheng Wu, Pinghui Xia, Tianyu He, Jinlin Cao, Wang Lv, Jian Hu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11681939.txt.
Description
After drug treatment shrinks a lung tumor before surgery, doctors can measure how much cancer is left in the removed tissue. Shihong Zhou and co-authors ask whether a major pathologic response, meaning very little live tumor remains, predicts survival in stage IIIA non-small cell lung cancer. They followed 38 patients who had at least two rounds of treatment before surgery, some with added immunotherapy.
Patients who reached a major response lived longer and stayed free of disease longer than those who did not. Among patients who missed that mark, extra rounds of treatment still helped, and adding immune therapy showed a trend toward better outcomes. The authors advise continuing treatment when a major response seems unlikely after two rounds.
Catalog record
| CREATOR | Shihong Zhou, Ying Zhang, Ziheng Wu, Pinghui Xia, Tianyu He, Jinlin Cao, Wang Lv, Jian Hu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |